Streptococcus pyogenes (GAS) is among the most diverse of all human pathogens, responsible 28 for a range of clinical manifestations, from mild superficial infections such as pharyngitis to 29 serious invasive infections such as necrotising fasciitis and sepsis. The drivers of these different 30 disease phenotypes are not known. The GAS cholesterol-dependent cytolysin, streptolysin O 31 (SLO), has well established cell and tissue destructive activity. We investigated the role of SLO 32 in determining disease outcome in vivo, by using two different clinical lineages; the recently 33 emerged hypervirulent outbreak emm type 32.2 strains, which result in sepsis, and the emm 34 type 1.0 strains which cause septic arthritis. Using clinically relevant in vivo mouse models of 35 sepsis and a novel septic arthritis model, we demonstrated that the amount and activity of SLO 36 is vital in determining the pathotype of infection. The emm32.2 strain produced large quantities 37 of highly haemolytic SLO that resulted in rapid development of sepsis. By contrast, the lower 38 levels and haemolytic activity of emm1.0 SLO led to translocation of bacteria to joints. 39 Importantly, sepsis associated strains that were attenuated by deletion or inhibition of SLO also 40 translocated to the joint, confirming the key role of SLO in determining infection niche. Our 41 findings demonstrate that SLO is key to in vivo pathotype and disease outcome. Careful 42 consideration should be given to novel therapy or vaccination strategies that target SLO. Whilst 43 neutralising SLO activity may reduce severe invasive disease, it has the potential to promote 44 chronic inflammatory conditions such as septic arthritis. 45 46 47 48 49 50 51 Group A Streptococcus (GAS), also called Streptococcus pyogenes, is a commensal of the 53 human upper respiratory tract and also an important human pathogen, accounting for over 750 54 million infections every year 1,2 . GAS is able to produce a variety of pyogenic infections that 55 range in severity and prevalence 3-5 . Diseases include pharyngitis, impetigo, cellulitis and more 56 life threating infections such as streptococcal toxic shock syndrome, necrotising fasciitis, and 57 sepsis 3,6 . The mechanisms that allow GAS to cause such diversity in disease types are 58 unknown, however a number of studies have shown that bacterial and host-specific components 59 may be involved 7 . 60 61 GAS strains are typed based on the sequence of the emm gene, which encodes the M-protein, 62 of which there are over 200 known emm types 8 . The epidemiology of GAS infections has been 63 changing globally over the last decade, with the emergence of new emm types and localised 64 outbreaks a main feature 9 . Within emm types of GAS, isolates may be causative of a range of 65 clinical outcomes, such that most lineages carry the potential for expression of a range of 66 phenotypes that may determine the course and nature of infection. Recent studies have shown 67 distinct correlations between the host niche of recovered GAS clinical isolates and their ability 68 to secrete high concentrations of known virulence factors such as streptococcal pyrogenic 69 exotoxin A, B, and C (SpeA, SpeB, and SpeC), or the haemolytic exotoxin streptolysin O 70 (SLO) 10-12 . In addition to this, the premise that GAS phenotypic heterogeneity contributes to 71 distinct clinical phenotypes is supported by studies that have found changes in virulence factor 72 production such as in streptokinase and capsular protein secretion after GAS is passaged either 73 ex vivo or in vivo [13][14][15][16][17] . 74 75 4
Introduction
To explain the clear differences in overall mouse survival, bacterial virulence and proliferation 150 in blood between the two emm type 1.0 and 32.2 isolates, we quantified the amount of SLO 151 secreted by each isolate in vitro (at equivalent CFU) by analysing the amount of SLO directly 152 secreted into the supernatant by the bacteria during growth phase in planktonic culture. The 153 concentration (ng/ml) of SLO produced by emm type 32.2 (isolate 112327) increased rapidly 154 over time compared with emm type 1.0 (isolate 101910); whereby isolate 112327 produced 155 significantly more SLO from 6 h onwards until the final time point at 12 h (p = 0.015 -156 <0.0001). Isolate 101910 produced a small amount of SLO initially but the concentration did 157 not continue to increase beyond 8 h ( Figure 3A ). We next looked at the haemolytic activity of 158 SLO. The haemolytic activity of SLO secreted by isolates 112327 and 101910 followed the 159 same pattern as that of the amount secreted; isolate 112327 SLO was significantly more 160 haemolytic from 6 h until the final time point at 12 h compared to isolate 101910 SLO (p = 161 0.028 -<0.0001) ( Figure 3B ). Hence, emm type 32.2 (isolate 112327) secreted not only 162 significantly more SLO than emm type 1.0 (isolate 101910), but also significantly more 163 haemolytic toxin at equivalent CFU. The CFU growth of both isolates was assessed to ensure 164 the differences observed for SLO were not due to significant differences in bacterial growth. 165 We found no significant difference in bacterial growth for both isolates across all time points, 166 with almost identical CFU loads at 10 and 12 h ( Figure 2C ), which interestingly were the same 167 time points with the greatest difference in SLO concentration and activity, suggesting that 168 bacterial growth rate and CFU load were not responsible for observed SLO differences between 169
isolates. 170
To further clarify the reasons for emm type 1.0 (isolate 101910) clearance from bloodstream 175 and translocation to the knee joints, we recovered bacteria from mouse knee joints at 24 h post 176 infection, and quantified the amount of SLO secreted into the supernatant over an in vitro 177 growth phase. We found that in vivo recovered isolate 101910 secreted significantly less SLO 178 into the supernatant over the 12 h in vitro growth phase. There was significantly less SLO 179 secreted from 6 h onward to that originally produced by isolate 101910 grown in vitro at 180 equivalent CFU (p = 0.009 -<0.0001) ( Figure 4A ). In addition to producing significantly less 181 SLO, the haemolytic activity of in vivo recovered bacterial SLO was also significantly lower 182 from 6 h to 10 h, again at equivalent CFU (p = 0.0007 -<0.0001), with SLO activity 183 comparable at 12 h ( Figure 4B ). We next wanted to determine whether in vivo recovered isolate 184 101910 retained its low SLO production and low SLO activity phenotype when grown over 185 multiple times in vitro. Interestingly, after just one growth phase in THYG culture, the 186 concentration of SLO reverted to a high SLO production phenotype (p = <0.0001) ( Figure 4C ), 187 with significantly increased haemolytic activity from 6 h to 10 h (p = <0.005) ( Figure 4D ), 188 suggesting that factors in vivo caused isolate 101910 to suppress its SLO production. During 189 intravenous infection with in vivo recovered isolate 101910 (10 7 CFU), bacteria enter the knee 190 joint at higher bacterial numbers and proliferate in the joint more quickly. These results suggest 191 that in vivo recovered emm type 1.0 (isolate 101910) is more adapted to initiating an infection 192 in the joint more quickly. 193
194

Concentration and activity of secreted SLO has significant impact on virulence in vivo 195
To investigate the effect of secreted SLO on virulence in vivo, we tested the amount and activity 196 of SLO released into the challenge inoculum (prior to infection of mice) of emm type 1.0 9 (isolate 101910) and emm type 32.2 (isolate 112327). At equivalent CFU challenge inoculum 198
(1 x 10 8 per 50 µl), isolate 112327 had significantly higher SLO concentration (p = 0.012) 199 ( Figure 5A ) and haemolytic activity (p = 0.01) ( Figure 5A ) than isolate 101910. This had a 200 direct effect on survival in vivo, where mice infected with isolate 112327 all died from their 201 infections, while those infected with isolate 101910 all survived ( Figure 5C ). 202
203
To further investigate the effect of secreted SLO on infection dose and survival, the 204 supernatants between isolates 112327 and 101910 were swapped prior to infection of the mice. 205
Infection doses were prepared in 1 ml of PBS, incubated at room temperature for 30 minutes, 206 immediately prior to infection bacteria were pelleted by centrifugation and the supernatants of 207 the two challenge doses were swapped. Mice were infected with either isolate 112327 bacteria 208 re-suspended in supernatant from isolate 101910 challenge dose or isolate 101910 bacteria re-209 suspended in supernatant from isolate 112327 challenge dose. In contrast to original challenge 210 dose infections, the supernatant swap infected mice exhibited the opposite phenotype, whereby 211 the normally non-lethal isolate 101910, now killed all mice when infected with supernatant 212 from isolate 112327, and the normally lethal isolate 112327 isolate became less virulent, 213 leading to only 50% death as compared to 100% death previously ( Figure 5C ). 214 observed, there were no CFUs of isolate 101910 in blood at 24 h, but a significant 4 Log 217 increase in CFUs was observed when isolate 101910 was infected with the supernatant swap 218 dose, clearly suggesting that the high concentration of SLO present in isolate 112327 219 supernatant was enabling proliferation and retention of isolate 101910 in blood as compared to 220 its normal condition of being cleared from blood ( Figure 5D ). In contrast, isolate 112327 221 challenge dose with isolate 101910 supernatant infected mice had significantly lower CFUs in 222 blood at 24 h in comparison to when infected with its original supernatant (p = 0.0079) ( Figure  223 5D) suggesting again, that the concentration and activity of SLO is key to virulence in vivo, 224 both in terms of survival and bacterial load. 225
226
SLO deficiency significantly reduces bacterial load and increases in vivo survival 227
To assess the role of SLO in the virulence of emm type 32.2 (isolate 112327) in vivo we 228 generated an isogenic SLO deletion mutant where the SLO gene was deleted and replaced by 229 a spectinomycin resistance gene through allelic exchange. All mice infected intravenously with 230 112327 ΔSLO mutant survived till the end of the experiment (96 h post infection), compared 231 to mice infected with the wild type isolate whom all succumbed to infection by 24h ( Figure  232 6A). The difference in mouse survival can be explained by the bacterial load in blood, which 233 was 3.5 log lower in the ΔSLO mutant by 24h post infection, than that observed in mice infected 234 with the wild type isolate (p = <0.0001) ( Figure 6B ). Furthermore, the bacterial burden of the 235 112327 ΔSLO mutant decreased over time and by 96 h post infection, bacteria were completely 236 cleared from the blood ( Figure 6B ). These results indicate that in the absence of the toxin, 237 bacteria were less able to establish an infection in the blood or were able to translocate 238 elsewhere. Indeed, as described before during infection with emm type 1.0 (isolate 101910), 239 mice infected with emm type 32.2 (isolate 112327) ΔSLO mutant also began to show joint 240 deformities by 24 h. We detected a high bacterial load in the knee joints, contrary to mice 241 infected with the wild type isolate in which no bacteria in knee joints or deformities were 242 observed ( Figure 6C ). Interestingly, we detected no difference in the bacterial burden in the 243 joints between 112327 ΔSLO mutant and emm type 1.0 (isolate 101910) ( Figure 6C ), which 244 demonstrates that the kinetics of the infection was the same across the two different isolates 245 and suggests that as well as being a key factor necessary and sufficient to virulence in vivo, 246 SLO is also intriguingly the driving factor in determining the phenotypic outcome of infection. 247 sphingomyelin liposomes; 66 mol/% cholesterol) as a method to sequester cholesterol 250 dependent cytolysins both in vitro and in vivo 31, 32 . We have shown that administration of 251 cholesterol rich liposomes within 10 h after initiation of infection stopped the progression of 252 bacteraemia caused by S. aureus and S. pneumoniae 31 and that liposomes were also able to 253 bind strongly to SLO 31,32 . Based on this, we now used specially tailored cholesterol rich 254 liposomes as targets to sequester secreted SLO in vivo. 255 256 Liposomes were successful in sequestering the toxin as the concentration of SLO was 257 significantly lower in emm type 32.2 (isolate 112327) supernatant when incubated with 258 liposomes as compared to non-liposome control (p = 0.003) ( Figure 7A ). When the bacterial 259 challenge dose was co-incubated with liposomes prior to infection, all mice infected with 260 liposome treated isolate 112327, survived a further 24 h as compared to non-liposome treated 261 control challenge dose ( Figure 7B ) and this extended survival period correlated with reduced 262 CFU load in blood ( Figure 7C ). In addition, the effects of giving liposomes as a treatment to 263 invasive GAS was also considered. A single injection of the liposomal mixture was 264 administered at 4 h post infection. All mice that were not liposome treated succumbed to 265 infection by 24 h, in comparison 60% of mice treated with the liposomal mixture survived an 266 extra 24 h to 48 h ( Figure 7D ). In line with the differences in survival time, there was a 267 considerable reduction of the bacterial load in the blood of mice that had been injected with a 268 single dose of liposomes at 4 h in comparison to no treatment group ( Figure 7E ). These results 269
show that a treatment with liposomes reduces the amount of SLO secreted into the extracellular 270 environment, leading to a considerable reduction of the bacterial burden in the blood of mice 271 and to attenuation of invasive GAS infection. 272
Discussion
273
In this study, we investigated the role of SLO in determining disease phenotype, and found that 274 differences in production and activity of SLO was central to in vivo pathotype and disease 275 outcome in GAS infections. 276
277
In summary, we found that SLO production and activity drove two very distinct in vivo 278 pathotypes; emm type 32.2 isolates which produced SLO in high levels and with high activity 279
and emm type 1.0 isolates, which were the exact opposite with low levels of SLO production 280 and of low activity. This correlated directly with their in vivo pathotype i.e. high virulence in 281 bacteraemia models accompanied by short host survival (emm type 32.2) and low virulence in 282 chronic septic arthritis models accompanied by long term host survival (emm type 1.0). Indeed, 283
we found that the levels and activity of SLO at time of initial infection, determined the disease 284 phenotype, with high levels of SLO driving invasive disease and low levels sustaining chronic 285 joint infections. When removing SLO from the in vivo environment, either by gene deletion or 286 by significantly reducing SLO (by supernatant swap or liposome sequestration method), we 287 were able to demonstrate a complete reversal in the in vivo pathotypes of these emm isolates, 288 whereby normally bacteraemia causing emm type 32.2 isolates could be made to translocate 289 into joints rather than killing their hosts, and septic arthritis causing emm type 1.0 isolates could 290 be made highly invasive, highlighting the crucial role of SLO in determining disease phenotype 291 and outcome in vivo. 292 293 SLO is a major virulence factor for GAS, expressed by nearly all strains, and with amino acid 294 sequence homology highly conserved between strains 33 . Multiple roles in pathogenicity in vivo 295 have been attributed to SLO, and recent studies have shown that SLO is important in the 296 evasion of the host response via a number of mechanisms. Timmer et al., demonstrated that 297 GAS induces rapid macrophage and neutrophil apoptosis due to the effects of SLO 24 , and 298 further work in the field has demonstrated that SLO rapidly impairs neutrophil oxidative burst 299 preventing the bactericidal action of neutrophils 34 . The effects of the general presence of 300 secreted SLO in the blood stream has been less well studied however, although it has been 301 implicated in driving inflammation, including the well documented evidence on activation of 302 the NLRP3 inflammasome 35 , hence, it would therefore seem likely that SLO production and 303 activity is important for GAS in invasive bacteraemia infections yet there has been no studies 304 to date to show that SLO itself could be driving disease phenotype in vivo. 305
306
Although the SLO gene is highly conserved among all emm types of GAS, studies have shown 307 that there are differences in the expression of the SLO gene which regulates the production of 308 secreted SLO 35 , and that specific invasive variants can be isolated post in vivo passage 13 . In 309 addition to this, it has been shown that in vivo conditions can result in differential expression 310 of certain proteins; a study looking at exotoxins SpeA and SpeB found that in vivo host and/or 311 The bacteria may secrete SLO during the infection but the initial challenge concentration 323 remains the key determinant resulting in clearance when concentrations are low and increased 324 virulence with higher concentrations. Interestingly, when we reversed this experiment and used 325 the supernatant from the challenge inoculum of high SLO secreting isolate 112327 and co-326 infected that with isolate 101910, we saw a complete change in the clinical phenotype, whereby 327 isolate 101910 was now able to successfully proliferate in the blood resulting in host death. 328
Taking both of these results together, they indicate that the amount of SLO that is initially 329 secreted is key to virulence in the early stages of infection, and it is possible for the host to 330 successfully clear the bacteria when SLO concentrations are low. Our data also shows that the 331 ability of the mice to survive infection is linked with the ability of the bacteria to proliferate. 332
Early studies on SLO indicated that it was toxic when injected directly in an animal model 28, 36 , 333 in our study administrating the supernatant alone into the mice without any bacteria did not 334 have a fatal effect. The difference with our study could be due to early studies using 335 supraphysiological concentrations of purified SLO and/or purified SLO preparations 336 contaminated with LPS. 337
338
To consider how the complete removal of SLO affects the progression of invasive infection, 339 an isogenic SLO deletion mutant of isolate 112327 was made. Our results demonstrate that 340 mice infected with the SLO mutant had a significantly higher rate of survival than mice infected 341 with its parent wild type bacteria. None of the mice infected with the mutant succumbed to 342 infection where as 100% of mice infected with the wildtype died at 24 h. The SLO mutant 343 began to be cleared from the blood as early as 24 h and was completely cleared by 96 h. 344 Surprisingly, we found that the SLO deficient mutant sequestered in the knee joints causing 345 septic arthritis as previously seen during infection with the low SLO secreting isolate 101910. 346
The results clearly show that GAS strains lacking SLO and or low SLO producing GAS strains are severely impaired in their ability to cause bacteraemia and that lack (or reduced levels) of 348 SLO enables the bacteria to accumulate within host joints. 349
350
There have been a number of previous studies using SLO mutants which have found that 351 virulence is attenuated, although the relative importance of SLO would appear to be dependent 352 on disease model used 23,28,29,37 . For example, Limbago et al., used a subcutaneous invasive 353 skin infection model to study the virulence of SLO-deficient mutants, where they found that 354 although there were increased survival times of mice infected with SLO deficient strains, the 355 absence of SLO itself did not limit dissemination from the wound into the vasculature 28 . In 356 contrast to this, a later study by Sierig et al., found that during a skin infection model initiated 357 by intraperitoneal infection there were no changes to survival using an SLO deficient mutant 358 23 . A more recent study looking at the emergence of an invasive emm type 89.0 clade, showed 359 that elevated SLO producers are significantly more virulent than low SLO producers 25 . Based 360 on our findings here, we speculate that the low production of SLO (or SLO deficiency) prevents 361 the ability of GAS to cause bacteraemia while enhancing its capability to translocate into the 362 joints. Low SLO secreting isolate 101910 which effectively colonises the joints, adapts further 363 to the joint by selecting for low secreting SLO variants. This is a selection pressure applied 364 from environmental signals in the joint as when the isolate is recovered from the joints and 365 placed under growth conditions in vitro it reverts to producing significantly more SLO (Figure  366 4C). Moreover, deletion of SLO in isolate 112327 resulted in a complete reversal of in vivo 367 phenotype, whereby these SLO deficient isolates now caused septic arthritis. 368
369
The exact mechanism by how GAS infects the joint is not clear. The general mechanism of 370 joint colonisation begins with haematogenous entry into the vascularised synovium. Once 371 bacteria are in the joint space the low fluid shear conditions provide a unique opportunity for 372 bacterial adherence and infection 38 . Different strains of bacteria that commonly infect the joint 373 including GAS and others such as S. aureus have varying degrees of tropism to the joint, 374 thought to be due to differences in adherence characteristics and toxin production 38 . We have 375 previously shown that isolate 112327 is an outbreak strain with characteristics that suggest it 376 is hypervirulent, e.g. it has 19 extra genes, five of which are associated with an increase in 377 virulence 39 . We have shown in this current study that isolate 112327 is more virulent in an 378 invasive bacteraemia model and produced significantly more SLO which is likely to be one of 379 the causes of its increased capacity to cause host death. 380 381 Infection with isolate 112327 results in uncontrolled bacterial proliferation in blood and rapid 382 progression into sepsis. On the other hand, isolate 101910 which was isolated from a patient 383 with septic arthritis and produces low concentrations of SLO, can be reduced to even lower 384 concentrations after further selection from the joint. This implies that decreased production of 385 SLO is beneficial during infection in the joint. Reduced or no expression of SLO could have a 386 protective effect for the pathogen, as SLO is immunogenic and avoiding host immune cell 387 detection could thereby prevent immune activation and clearance, allowing GAS to continue 388 to colonise the joint 21 . 389
390
The results presented here have important implications for our understanding of GAS 391 pathogenesis. We conclude that levels and activity of SLO is key to determining whether GAS 392 infection follows an highly invasive and virulent pattern leading to host death or whether it 393 follows a chronic pattern of long term joint infection. The fact that these disease phenotypes 394 are not fixed is highly interesting, as it suggest that GAS is highly sensitive to environmental 395 signals and can change its phenotype rapidly. Indeed, by artificially effecting SLO levels, we 396 have shown that one disease phenotype can easily be switched into another. This has significant implications for therapy and vaccines as anti-SLO based treatments may not be the complete 398 answer to protection against all forms of GAS infection. 399 400 The plasmid was transformed into E. coli DH5α competent cells (ThermoFischer Scientific). 507
Materials and methods
The aad9 gene was amplified by PCR using primers aad9-F and aad9-R. The PCR product was 508 subcloned into pGEM-T-∆slo-2kb at the BamHI restriction site, generating pGEM-T-509 ∆slo::aad9, which interrupted the slo fragment, providing a means of positive selection of 510 transformants. The generated plasmid was transformed into emm type 32.2 isolate 112327 by 511 electroporation as previously described 46 . Transformants were recovered on THY agar 512 supplemented with spectinomycin (100 µg/mL) at 37°C in a candal jar for up to 72 h. SLO 513 deletion was identified by PCR and the PCR products were sequenced to confirm authenticity 514 of the insertion. 515
516
In vivo invasive model-switching supernatant of isolates 517
Frozen bacterial stocks were thawed at room temperature and 10 7 bacteria were prepared in 1 518 ml PBS. After 30 mins both strains were centrifuged at 14,000 x g for 2 mins, the supernatant 519 from emm type 32.2 (isolate 112327) was used to re-suspend emm type 1.0 (isolate 101910) 520 bacteria and the supernatant from emm type 1.0 (isolate 101910) was used to re-suspend emm 521 type 32.2 (isolate 112327) bacteria. Mice were immediately infected. The supernatants were 522 analysed using the SLO-ELISA to measure the amount SLO present in ng/ml. Mice were 523 humanely culled when they were scored '++lethargic' and blood tissue was collected for CFU 524 enumeration. 525 526 Liposomes 527
Liposomes were generated with cholesterol and sphingomyelin from egg yolk from Sigma and 528 dissolved in chloroform at 100 and 50mg/ml respectively. Lipids were mixed together 529 with cholesterol at 66 mol/% proportion and then evaporated with nitrogen gas for 30min. For 530 Cholesterol: Sphingomyelin (Ch:Sm) large and small liposomes, the hydration was made by 531 addition of PBS (ThermoFisher scientific) and incubated at 55°C for 30 mins with vortexing. 532
To obtain small unilamellar particles, the liposome preparation was then subsequently 533 sonicated for 30min at 4°C. To eliminate carboxyfluorescein, the preparation was diluted in 534 PBS and applied to a Sephadex G-25 column in PD-10 (GE Healthcare). Particle concentration 535 and size distribution of the liposomes generated were evaluated using the NanoSight NS300 536 instrument (Malvern, UK) and using Nanoparticle Tracking Analysis (NTA) software. The shifting epidemiology of Streptococcus pyogenes (GAS) infections globally over the past 556 decade has been punctuated by emm type emergence and localised outbreaks of severe invasive 557 disease. Within emm types there is diversity of possible clinical outcomes, however, the basis 558 of these varied clinical phenotypes is not well understood. To address this question, we 559 investigated the role of GAS virulence and its host interactions. We discovered that streptolysin 560 
